- Home
- BBIO vs PATH Comparison
BBIO vs PATH Comparison
Compare BBIO & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- PATH
- Stock Information
- Founded
- BBIO 2015
- PATH 2005
- Country
- BBIO United States
- PATH United States
- Employees
- BBIO N/A
- PATH N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- PATH Computer Software: Prepackaged Software
- Sector
- BBIO Health Care
- PATH Technology
- Exchange
- BBIO Nasdaq
- PATH Nasdaq
- Market Cap
- BBIO 7.6B
- PATH 7.1B
- IPO Year
- BBIO 2019
- PATH 2021
- Fundamental
- Price
- BBIO $41.73
- PATH $12.19
- Analyst Decision
- BBIO Strong Buy
- PATH Hold
- Analyst Count
- BBIO 13
- PATH 18
- Target Price
- BBIO $56.67
- PATH $13.97
- AVG Volume (30 Days)
- BBIO 2.5M
- PATH 13.6M
- Earning Date
- BBIO 07-31-2025
- PATH 05-29-2025
- Dividend Yield
- BBIO N/A
- PATH N/A
- EPS Growth
- BBIO N/A
- PATH N/A
- EPS
- BBIO N/A
- PATH N/A
- Revenue
- BBIO $127,415,000.00
- PATH $1,451,176,000.00
- Revenue This Year
- BBIO $102.05
- PATH $10.73
- Revenue Next Year
- BBIO $54.69
- PATH $8.72
- P/E Ratio
- BBIO N/A
- PATH N/A
- Revenue Growth
- BBIO N/A
- PATH 7.21
- 52 Week Low
- BBIO $21.62
- PATH $9.38
- 52 Week High
- BBIO $41.90
- PATH $15.93
- Technical
- Relative Strength Index (RSI)
- BBIO 69.82
- PATH 43.26
- Support Level
- BBIO $39.65
- PATH $12.17
- Resistance Level
- BBIO $41.36
- PATH $12.59
- Average True Range (ATR)
- BBIO 1.51
- PATH 0.39
- MACD
- BBIO 0.35
- PATH -0.14
- Stochastic Oscillator
- BBIO 97.37
- PATH 9.95
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.